{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:24:12Z","timestamp":1790288652317,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013873","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T19:52:46Z","timestamp":1721073166000},"page":"e861-e869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pomalidomide Use and Kidney Outcomes in Patients With Relapsed\/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-1235","authenticated-orcid":false,"given":"Alejandro","family":"Meraz-Munoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5147-8210","authenticated-orcid":false,"given":"David","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivethika","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-4368","authenticated-orcid":false,"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2024.07.007_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clml.2024.07.007_bib0002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.14394","article-title":"A population-based study of the impact of dialysis on mortality in multiple myeloma","volume":"180","author":"Evison","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.07.007_bib0003","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ndt\/gfz211","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry","volume":"36","author":"Courant","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1016\/j.clml.2024.07.007_bib0004","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.3390\/cancers13205036","article-title":"Advances in the treatment of relapsed and refractory multiple myeloma in patients with renal insufficiency: novel agents, immunotherapies and beyond","volume":"13","author":"Bozic","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.clml.2024.07.007_bib0005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Pieter","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.07.007_bib0006","unstructured":"Inc. C. Health canada approves Pomalyst\u00ae-based triplet combination for patients with multiple myeloma. Accessed Feb 8, 2024, Available at: https:\/\/www.newswire.ca\/news-releases\/health-canada-approves-pomalyst-r-based-triplet-combination-for-patients-with-multiple-myeloma-843712407.html."},{"issue":"18","key":"10.1016\/j.clml.2024.07.007_bib0007","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.07.007_bib0008","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2024.07.007_bib0009","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.clml.2024.07.007_bib0010","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: results from a phase II trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.07.007_bib0011","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.07.007_bib0012","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.07.007_bib0013","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.07.007_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.07.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2024.07.007_bib0016","unstructured":"Ontario demographics. Accessed September 09, 2022, Available at: https:\/\/www.ontario.ca\/page\/ontario-demographics."},{"issue":"1","key":"10.1016\/j.clml.2024.07.007_bib0017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-021-00602-4","article-title":"Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2024.07.007_bib0018","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario drug benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol. Summer"},{"issue":"5","key":"10.1016\/j.clml.2024.07.007_bib0019","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2215\/CJN.10821011","article-title":"Estimating baseline kidney function in hospitalized patients with impaired kidney function","volume":"7","author":"Siew","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.clml.2024.07.007_bib0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.34067\/KID.0006082021","article-title":"Defining baseline creatinine for identification of AKI in population-based laboratory databases: a Danish nationwide cohort study","volume":"3","author":"Graversen","year":"2022","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.clml.2024.07.007_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clml.2024.07.007_bib0022","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1-4","key":"10.1016\/j.clml.2024.07.007_bib0023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000363725","article-title":"Clinical trial endpoints in acute kidney injury","volume":"127","author":"Billings","year":"2014","journal-title":"Nephron Clinical Practice"},{"issue":"6","key":"10.1016\/j.clml.2024.07.007_bib0024","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00134-017-4732-1","article-title":"What endpoints should be used for clinical studies in acute kidney injury?","volume":"43","author":"Kellum","year":"2017","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.clml.2024.07.007_bib0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10916-016-0528-z","article-title":"Identification of major adverse kidney events within the electronic health record","volume":"40","author":"Semler","year":"2016","journal-title":"J Med Syst"},{"issue":"2","key":"10.1016\/j.clml.2024.07.007_bib0026","first-page":"236","article-title":"Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib","volume":"23","author":"Chen","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2024.07.007_bib0027","doi-asserted-by":"crossref","unstructured":"Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States. BMC Cancer. 2022;22(1):901. doi:10.1186\/s12885-022-09980-9.","DOI":"10.1186\/s12885-022-09980-9"},{"issue":"4","key":"10.1016\/j.clml.2024.07.007_bib0028","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","article-title":"Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors","volume":"9","author":"Dimopoulos","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"12","key":"10.1016\/j.clml.2024.07.007_bib0029","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.282905","article-title":"Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study","volume":"14","author":"McCurdy","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2024.07.007_bib0030","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ckj\/sfad022","article-title":"Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view","volume":"16","author":"Terrades","year":"2023","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1016\/j.clml.2024.07.007_bib0031","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1080\/10428194.2016.1177181","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials","volume":"57","author":"Siegel","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.07.007_bib0032","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hon.2290","article-title":"Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed\/refractory multiple myeloma and severe renal dysfunction: a case series","volume":"35","author":"Richter","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.07.007_bib0033","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bjh.14547","article-title":"Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience","volume":"176","author":"Maciocia","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:10:15Z","timestamp":1729595415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002659"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pomalidomide Use and Kidney Outcomes in Patients With Relapsed\/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}